Patents Represented by Attorney, Agent or Law Firm Timothy E. Torchia
-
Patent number: 5702906Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4.beta., NT-4.gamma., and NT-4.DELTA.. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.Type: GrantFiled: May 26, 1995Date of Patent: December 30, 1997Assignee: Genentech, Inc.Inventor: Arnon Rosenthal
-
Patent number: 5688681Abstract: The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.Type: GrantFiled: June 13, 1994Date of Patent: November 18, 1997Assignee: Genentech, Inc.Inventor: Kyung Jin Kim
-
Patent number: 5679545Abstract: Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. These CT-1 molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: May 17, 1995Date of Patent: October 21, 1997Assignees: Genentech, Inc., The Regents of the University of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
-
Patent number: 5677178Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.Type: GrantFiled: April 29, 1996Date of Patent: October 14, 1997Assignee: ONYX Pharmaceuticals, Inc.Inventor: Francis McCormick
-
Patent number: 5674984Abstract: Methods for producing and isolating unclipped HIV env proteins are provided. According to the methods, an antibody directed to an HIV epitope spanning the env clip site is used to selectively separate unclipped HIV env protein from clipped env protein.Type: GrantFiled: April 11, 1994Date of Patent: October 7, 1997Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Florian M. Wurm
-
Patent number: 5668003Abstract: The invention relates to nucelic acids encoding monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.Type: GrantFiled: May 10, 1995Date of Patent: September 16, 1997Assignee: Genentech, Inc.Inventor: Kyung Jin Kim
-
Patent number: 5654157Abstract: The invention relates to immunoassays utilizing monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.Type: GrantFiled: May 10, 1995Date of Patent: August 5, 1997Assignee: Genentech, Inc.Inventor: Kyung Jin Kim
-
Patent number: 5627073Abstract: Isolated CHF (also referred to cardiac hypertrophy factor or cardiotrophin-1), isolated DNA encoding CHF, hybridomas and cell lines producing antibodies to CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: May 17, 1995Date of Patent: May 6, 1997Assignees: Genentech, Inc., The Regents of the University of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
-
Patent number: 5624806Abstract: Isolated CHF, isolated DNA encoding cardiac hypertrophy factor (CHF), and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: May 17, 1995Date of Patent: April 29, 1997Assignees: Genentech, Inc., The Regents of the University of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
-
Patent number: 5589167Abstract: Methods for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with trehalose, a polyol having a molecular weight less than about 70,000 kD.Type: GrantFiled: April 8, 1994Date of Patent: December 31, 1996Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Andrew J. S. Jones
-
Patent number: 5573762Abstract: A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.Type: GrantFiled: April 24, 1995Date of Patent: November 12, 1996Assignee: Genentech, Inc.Inventors: Napoleone Ferrara, Kathleen King, Elizabeth Luis, Jennie P. Mather, Nicholas F. Paoni
-
Patent number: 5571893Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed, These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: August 5, 1994Date of Patent: November 5, 1996Assignees: Genentech, Inc., Regents of the Univ. of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
-
Patent number: 5571675Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: May 17, 1995Date of Patent: November 5, 1996Assignees: Genentech, Inc., Regents of the Univ. of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
-
Patent number: 5534615Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: April 25, 1994Date of Patent: July 9, 1996Assignees: Genentech, Inc., The Regents of the University of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennice, William Wood
-
Patent number: 5518911Abstract: A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity.Type: GrantFiled: January 6, 1995Date of Patent: May 21, 1996Assignee: Onyx Pharmaceuticals, Inc.Inventors: Arie Abo, George A. Martin